[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352962-105":59,"doc-detail-352962-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","anp32e-drives-lung-adenocarcinoma-progression-via-gsk3-mediated-glycolytic-reprogramming","ANP32E drives lung adenocarcinoma progression via GSK3β-mediated glycolytic reprogramming","","ANP32E is identified as a key regulator of lung adenocarcinoma progression through epigenetic-metabolic coupling. Multi-omics and clinical analyses link ANP32E overexpression to poor prognosis, while ANP32E knockdown suppresses LUAD proliferation, migration, glycolysis, and xenograft growth and overexpression promotes tumorigenesis. Mechanistically, ANP32E increases KDM3B to reduce H3K9me2 at the EGFR promoter, activating PI3K/AKT and inhibitory GSK3β phosphorylation, culminating in oncogenic glycolysis. KDM3B silencing or EGFR inhibition blocks these phenotypes. Screening highlights PGG as an ANP32E-targeting compound that inhibits the ANP32E/KDM3B/EGFR axis in vitro and suppresses tumor growth in vivo.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/anp32e-drives-lung-adenocarcinoma-progression-via-gsk3-mediated-glycolytic-reprogramming/352962/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/anp32e-drives-lung-adenocarcinoma-progression-via-gsk3-mediated-glycolytic-reprogramming/352962.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does ANP32E play in lung adenocarcinoma (LUAD)?","Question",{"text":112,"@type":113},"ANP32E acts as a key regulator driving LUAD progression. Its overexpression correlates with poor prognosis and functionally promotes proliferation, migration, glycolysis, and tumor growth.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does ANP32E mechanistically connect epigenetic changes to metabolic reprogramming?",{"text":117,"@type":113},"ANP32E transcriptionally upregulates KDM3B, which reduces repressive H3K9me2 marks at the EGFR promoter to enhance EGFR transcription. EGFR activation then stimulates PI3K/AKT signaling, leading to inhibitory phosphorylation of GSK3β and enabling oncogenic glycolysis.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports ANP32E as a therapeutic target?",{"text":121,"@type":113},"High-throughput screening identified PGG as an ANP32E-targeting compound. PGG dose-dependently inhibits the ANP32E/KDM3B/EGFR axis in vitro and suppresses tumor growth in vivo, consistent with ANP32E-driven phenotypes being disrupted.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352962,1790194391,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nANP32E drives lung adenocarcinoma progression via GSK3β-mediated glycolytic reprogramming  \nZhongliang Wang1,5, Qianxia Li2,5, Zeguang Ye3, Xi Wu3, Can Fang3, Wenyang Jiang4 ✉ and Min Zhu 3 ✉© The Author(s) 2026, modiﬁed publication 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | Lung adenocarcinoma (LUAD), a leading cause of cancer mortality, involves incompletely understood epigenetic-metabolic crosstalk. We identiﬁed ANP32E as a key regulator through multi-omics (TCGA, scRNA-seq) and clinical analyses, ﬁnding its overexpression correlates with poor prognosis. Functionally, ANP32E knockdown suppressed proliferation, migration, and glycolysis in LUAD cells (A549/H1975) and attenuated xenograft growth, while overexpression promoted tumorigenesis. Mechanistically, ANP32E transcriptionally upregulates histone demethylase KDM3B, reducing repressive H3K9me2 marks at the EGFR promoter to enhance EGFR transcription. This activates PI3K/AKT signaling, inducing inhibitory GSK3β phosphorylation. Combined with ANP32Emediated GSK3β suppression, this dual inactivation liberates oncogenic glycolysis. Crucially, KDM3B silencing or EGFR inhibition (Cetuximab) abrogated ANP32E-driven phenotypes. High-throughput screening identiﬁed Penta-O-galloyl-β-D-glucose (PGG) as an ANP32E-targeting compound, with molecular dynamics conﬁrming binding. PGG dose-dependently inhibited the ANP32E/KDM3B/ EGFR axis in vitro and suppressed tumor growth in vivo. Thus, ANP32E drives LUAD progression via KDM3B/EGFR-mediated GSK3β |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| inactivation, representing a prognostic biomarker and therapeutic target validated by PGG. |  |  |\n|  | Cell Death and Disease (2026)17:503; [https://doi.org/10.1038/s41419-026-08712-2](https://doi.org/10.1038/s41419-026-08712-2) |  |\n|  |  |  |\n\nINTRODUCTION  \nLung cancer is a leading cause of cancer—related mortality globally, with lung adenocarcinoma (LUAD) being its most prevalent subtype [1] . Despite advances in treatment modalities, the prognosis for LUAD patients remains poor due to its aggressive nature and complex pathogenesis. Recent research has highlighted the importance of metabolic reprogramming, particularly enhanced glycolysis, in driving tumor progression. This metabolic shift not only meets the energy demands of rapidly proliferating cancer cells but also facilitates biosynthesis and redox balance, thereby conferring a growth advantage [2] .  \nThe PI3K/AKT signaling pathway is a central regulator of various cellular processes, including metabolism, proliferation, and survival [3] . Its activation often correlates with a more malignant phenotype in cancers. AKT, a key downstream effector of PI3K, can phosphorylate and inactivate GSK3β [4] . Inactive GSK3β contributes to the stabilization of multiple oncoproteins and the activation of metabolic pathways, including glycolysis [5–7] . Epidermal growth factor receptor (EGFR), a central oncogenicdriver in LUAD, not only stimulates proliferative signaling but also directly modulates glycolytic metabolism via downstream pathways, including PI3K/AKT [8–12] . While EGFR activation is commonly attributed to genetic mutations, emerging evidence highlights epigenetic dysregulation as a critical mechanism governing its transcriptional expression.  \nHistone lysine methylation is dynamically regulated through reversible modiﬁcations orchestrated by speciﬁc methyltransferases and demethylases [13, 14] . During development, H3K9 methylation states are precisely controlled by the balanced activity of these opposing enzymes [15–17] . The KDM3 demethylase family—comprising KDM3A, KDM3B, and JMJD1C—features a conserved Jumonji C (JmjC) domain conferring H3K9me1/me2 demethylase activity [18–21] . As a key member, KDM3B speciﬁcally demethylates H3K9me2, promoting chromatin relaxation and transcriptional activation of target genes [22","cbCaiparz2Xk0wZe","https://ap.wps.com/l/cbCaiparz2Xk0wZe","pdf",6218581,13,"English","# Introduction\n## Lung cancer and glycolytic metabolic reprogramming\n## PI3K/AKT signaling and GSK3β regulation\n## EGFR-driven metabolic and epigenetic mechanisms\n## Histone lysine methylation and KDM3B function\n## ANP32E biology and oncogenic roles","[{\"question\":\"What role does ANP32E play in lung adenocarcinoma (LUAD)?\",\"answer\":\"ANP32E acts as a key regulator driving LUAD progression. Its overexpression correlates with poor prognosis and functionally promotes proliferation, migration, glycolysis, and tumor growth.\"},{\"question\":\"How does ANP32E mechanistically connect epigenetic changes to metabolic reprogramming?\",\"answer\":\"ANP32E transcriptionally upregulates KDM3B, which reduces repressive H3K9me2 marks at the EGFR promoter to enhance EGFR transcription. EGFR activation then stimulates PI3K/AKT signaling, leading to inhibitory phosphorylation of GSK3β and enabling oncogenic glycolysis.\"},{\"question\":\"What evidence supports ANP32E as a therapeutic target?\",\"answer\":\"High-throughput screening identified PGG as an ANP32E-targeting compound. PGG dose-dependently inhibits the ANP32E/KDM3B/EGFR axis in vitro and suppresses tumor growth in vivo, consistent with ANP32E-driven phenotypes being disrupted.\"}]","ANP32E drives lung adenocarcinoma progression via GSK3β-mediated glycolytic reprogramming | PDF",1790102326,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a338a6e40d517c49543904cac63e8b9.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c5772e5ef77eb702f08dee715b46b194.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2ec49a0d7439ef44a072e16238749f7f.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7ad260ad10f366dbdc67c212a1c41043.webp",980,1301]